Datapoint: Rigel’s New AML Drug Will Face Off Against Tibsovo

The FDA last week approved Rigel Pharmaceuticals’ Rezlidhia for the treatment of relapsed or refractory acute myeloid leukemia (AML) with the IDH1 mutation in adult patients. The drugmaker in August paid just $2 million to Forma Therapeutics for Rezlidhia’s exclusive licensing rights. The approval means Rezlidhia will go head-to-head with Servier’s Tibsovo, which scored a nod for IDH1-mutated AML in May. For the treatment of AML, Tibsovo currently holds covered or better status for 96% of all insured lives under the pharmacy benefit. About 29% of insured lives have preferred access to Tibsovo, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 12/5/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 29

Datapoint: FDA Approves Latest Humira Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 28

Datapoint: Xolair Scores FDA Nod for Food Allergies

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 27

Datapoint: Aetna Sees Strong MA Growth

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today